Defining patients at risk for neoplastic meningitis: what parameters can be used to determine who should be treated?
While a growing body of clinical research is defining how better to treat neoplastic meningitis, questions regarding which parameters can be used to define who to treat remain. This discussion initiates the clinical core and practical components of the symposium.
Chamberlain
Marc C
MC
USC/Norris Cancer Center, Department of Neurology, 1441 Eastlake Ave., Suite 3459, Los Angeles, CA 90033-0804, USA. chamberl@usc.edu
Junck
Larry
L
D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D012306:Risk